We are live on
!
Find out more
SL
Siren LLC Portfolio holdings
AUM
$3.61B
1-Year Est. Return
203.3%
This Fund
S&P 500
This Quarter
Est. Return
+18.65%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$160M
(+9%)
Cap. Flow
+$578K
Cap. Flow
% of AUM
0.03%
Top 10 Holdings %
Top 10 Hldgs %
48.49%
Holding
131
New
15
Increased
21
Reduced
19
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dyne Therapeutics
DYN
|
+$23.3M |
| 2 |
BCAX
Bicara Therapeutics
BCAX
|
+$23.2M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$21.1M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$20.7M |
| 5 |
ArriVent BioPharma
AVBP
|
+$14.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$64.3M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$19.5M |
| 3 |
Prothena Corp
PRTA
|
+$15.9M |
| 4 |
Summit Therapeutics
SMMT
|
+$13.4M |
| 5 |
NewAmsterdam Pharma
NAMS
|
+$13.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.42% |
| 2 | Technology | 4.93% |
| 3 | Communication Services | 2.51% |
| 4 | Consumer Discretionary | 1.07% |
| 5 | Real Estate | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Neumora Therapeutics
NMRA
$302M
| $3.2M | 0.17% |
4,358,283
| – | – |
|
77
ProQR Therapeutics
PRQR
$265M
| $3.17M | 0.16% |
1,552,183
| – | – |
|
|
NBIS
78
Nebius Group N.V.
NBIS
$47.7B
| $2.82M | 0.15% |
51,000
-89,000
| -64% | -$3.06M |
|
79
Black Diamond Therapeutics
BDTX
$112M
| $2.6M | 0.13% |
1,046,517
| – | – |
|
80
Lexeo Therapeutics
LXEO
$378M
| $2.43M | 0.13% |
603,435
| – | – |
|
81
Palo Alto Networks
PANW
$297B
| $2.35M | 0.12% |
11,500
| – | – |
|
82
Qualcomm
QCOM
$176B
| $2.23M | 0.12% |
14,000
| – | – |
|
83
Workiva
WK
$3.54B
| $1.92M | 0.1% |
28,000
+10,500
| +60% | +$722K |
|
84
Eledon Pharmaceuticals
ELDN
$285M
| $1.87M | 0.1% |
690,170
| – | – |
|
85
KE Holdings
BEKE
$18.8B
| $1.86M | 0.1% |
105,000
| – | – |
|
86
HubSpot
HUBS
$10.5B
| $1.67M | 0.09% |
+3,000
| New | +$1.76M |
|
87
UnitedHealth
UNH
$370B
| $1.58M | 0.08% |
+5,076
| New | +$1.94M |
|
|
BIOA
88
BioAge Labs
BIOA
$538M
| $1.58M | 0.08% |
382,406
| – | – |
|
89
GitLab
GTLB
$6.58B
| $1.58M | 0.08% |
+35,000
| New | +$1.6M |
|
|
TRML
90
DELISTED
Tourmaline Bio
TRML
| $1.46M | 0.08% |
91,426
| – | – |
|
91
Rocket Pharmaceuticals
RCKT
$394M
| $1.45M | 0.08% |
591,263
| – | – |
|
92
Tesla
TSLA
$1.3T
| $1.27M | 0.07% |
4,000
-5,000
| -56% | -$1.51M |
|
93
Birkenstock
BIRK
$7.07B
| $1.23M | 0.06% |
+25,000
| New | +$1.29M |
|
|
SAIL
94
SailPoint Inc
SAIL
$10.6B
| $1.14M | 0.06% |
50,000
-45,000
| -47% | -$850K |
|
|
SEMR
95
DELISTED
Semrush
SEMR
| $1.13M | 0.06% |
125,000
| – | – |
|
|
PRMB
96
Primo Brands
PRMB
$8.54B
| $1.11M | 0.06% |
+37,500
| New | +$1.2M |
|
97
Cellebrite
CLBT
$3.99B
| $960K | 0.05% |
+60,000
| New | +$1.07M |
|
|
GBIO
98
DELISTED
Generation Bio
GBIO
| $950K | 0.05% |
296,893
| – | – |
|
|
KLRS
99
Kalaris Therapeutics
KLRS
$96.8M
| $755K | 0.04% |
282,586
| – | – |
|
|
HOOK
100
DELISTED
HOOKIPA Pharma
HOOK
| $711K | 0.04% |
566,640
| – | – |
|
Similar funds
SCM
ACM
GCM
VI
BPS
VPC
WWA
OCM
Siren LLC's Q2 2025 Portfolio in Review
As of Q2 2025, Siren LLC held 131 positions worth $1.93B, up 9% from $1.77B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Siren LLC's Q2 2025 filing shows 15 new, 21 increased, 19 reduced and 21 closed positions. Its largest new stake was MoonLake Immunotherapeutics: 508,267 shares worth $24M. The largest sale was Blueprint Medicines, an estimated $64.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Technology and Communication Services.
- Siren LLC's largest Q2 2025 buy was MoonLake Immunotherapeutics: 508,267 shares worth $24M.
- Siren LLC added most to Dyne Therapeutics in Q2 2025, an estimated $23.3M increase.
- Siren LLC's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $19.5M.
- Siren LLC fully exited Blueprint Medicines in Q2 2025, selling an estimated $64.3M.
- Siren LLC's ten largest holdings make up 48% of its $1.93B portfolio in Q2 2025.
- Siren LLC opened 15 new positions and closed 21 in Q2 2025.
- Siren LLC's portfolio value rose 9% quarter-over-quarter to $1.93B.
Based on Siren LLC's 13F filing for Q2 2025, filed 13 Aug 2025.